Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions

• Katherine E. Cornish ,

  * E-mail: corni026@umn.edu

  Affiliations Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States of America

  ⨯
• Sabina H. L. de Villiers,

  Affiliations Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States of America, Center for Global Studies and Social Responsibility, University of Minnesota, Minneapolis, Minnesota, United States of America, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

  ⨯
• Marco Pravetoni,

  Affiliations Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States of America, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America

  ⨯
• Paul R. Pentel

  Affiliations Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, United States of America, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, United States of America, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America

  ⨯